Panos Kanavos
Panos Kanavos
Associate Professor in International Health Policy
Подтвержден адрес электронной почты в домене lse.ac.uk - Главная страница
НазваниеПроцитированоГод
The rising burden of cancer in the developing world
P Kanavos
Annals of oncology 17 (suppl_8), viii15-viii23, 2006
4692006
Assessing the economic challenges posed by orphan drugs
MF Drummond, DA Wilson, P Kanavos, P Ubel, J Rovira
International journal of technology assessment in health care 23 (1), 36-42, 2007
2642007
Encouraging the use of generic medicines: implications for transition economies
DR King, P Kanavos
Croatian medical journal 43 (4), 462-469, 2002
2142002
Ensuring value for money in health care: the role of health technology assessment in the European Union
C Sorenson, M Drummond, P Kanavos
WHO Regional Office Europe, 2008
2002008
Diabetes expenditure, burden of disease and management in 5 EU countries
P Kanavos, S van den Aardweg, W Schurer
LSE Health and Social Care, 2012
1632012
Competition in off-patent drug markets: Issues, regulation and evidence
P Kanavos, J Costa-Font, E Seeley
Economic policy 23 (55), 500-544, 2008
1512008
Reference pricing for drugs: is it compatible with US health care?
P Kanavos, U Reinhardt
Health Affairs 22 (3), 16-30, 2003
1502003
Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom
SG Morgan, M McMahon, C Mitton, E Roughead, R Kirk, P Kanavos, ...
Health Affairs 25 (2), 337-347, 2006
1462006
Socio-economic burden of rare diseases: a systematic review of cost of illness evidence
A Angelis, D Tordrup, P Kanavos
Health Policy 119 (7), 964-979, 2015
1192015
Pharmaceutical parallel trade in Europe: stakeholder and competition effects
P Kanavos, J Costa-Font
Economic policy 20 (44), 758-798, 2005
1152005
Do generics offer significant savings to the UK National Health Service?
P Kanavos
Current medical research and opinion 23 (1), 105-116, 2007
1022007
The economic impact of pharmaceutical parallel trade in European Union member states: A stakeholder analysis
P Kanavos, J Costa-i-Font, S Merkur, M Gemmill
London: LSE Health and Social Care Special Research Paper, 2004
972004
Managed entry agreements for pharmaceuticals: the European experience
A Ferrario, P Kanavos
EMINet, 2013
952013
Epidemiology, management, complications and costs associated with type 2 diabetes in Brazil: a comprehensive literature review
AD Bertoldi, P Kanavos, GVA França, A Carraro, CAO Tejada, PC Hallal, ...
Globalization and health 9 (1), 62, 2013
922013
Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden
A Ferrario, P Kanavos
Social science & medicine 124, 39-47, 2015
892015
Differences in costs of and access to pharmaceutical products in the EU
P Kanavos, S Vandoros, R Irwin, E Nicod, M Casson
European Parliament, 2011
882011
Early chronic kidney disease: diagnosis, management and models of care
OJ Wouters, DJ O'donoghue, J Ritchie, PG Kanavos, AS Narva
Nature Reviews Nephrology 11 (8), 491, 2015
872015
Symptomatic vitreomacular adhesion
TL Jackson, E Nicod, A Simpson, A Angelis, F Grimaccia, P Kanavos
Retina 33 (8), 1503-1511, 2013
832013
Pars plana vitrectomy for vitreomacular traction syndrome: a systematic review and metaanalysis of safety and efficacy
TL Jackson, E Nicod, A Angelis, F Grimaccia, AT Prevost, ARH Simpson, ...
Retina 33 (10), 2012-2017, 2013
822013
Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs
P Kanavos, A Ferrario, S Vandoros, GF Anderson
Health affairs 32 (4), 753-761, 2013
772013
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20